Cannabis-based products have experienced notable increases
in co-usage
alongside tobacco products. Several cannabinoids exhibit inhibition
of a number of cytochrome P450 (CYP) and UDP glucuronosyltransferase
(UGT) enzymes, but few studies have examined their inhibition of enzymes
involved in nicotine metabolism. The goal of the present study was
to examine potential drug–drug interactions occurring in the
nicotine metabolism pathway perpetrated by cannabidiol (CBD) and its
active metabolite, 7-hydroxy-CBD (7-OH-CBD). The inhibitory effects
of CBD and 7-OH-CBD were tested in microsomes from HEK293 cells overexpressing
individual metabolizing enzymes and from human liver tissue. Assays
with overexpressing microsomes demonstrated that CBD and 7-OH-CBD
inhibited CYP-mediated nicotine metabolism. Binding-corrected IC50,u values for CBD inhibition of nicotine metabolism to cotinine
and nornicotine, and cotinine metabolism to trans-3′-hydroxycotinine (3HC), were 0.27 ± 0.060, 0.23 ±
0.14, and 0.21 ± 0.14 μM, respectively, for CYP2A6; and
0.26 ± 0.17 and 0.029 ± 0.0050 μM for cotinine and
nornicotine formation, respectively, for CYP2B6. 7-OH-CBD IC50,u values were 0.45 ± 0.18, 0.16 ± 0.08, and 0.78 ±
0.23 μM for cotinine, nornicotine, and 3HC formation, respectively,
for CYP2A6, and 1.2 ± 0.44 and 0.11 ± 0.030 μM for
cotinine and nornicotine formation, respectively, for CYP2B6. Similar
IC50,u values were observed in HLM. Inhibition (IC50,u = 0.37 ± 0.06 μM) of 3HC to 3HC-glucuronide
formation by UGT1A9 was demonstrated by CBD. Significant inhibition
of nicotine metabolism pathways by CBD and 7-OH-CBD suggests that
cannabinoids may inhibit nicotine metabolism, potentially impacting
tobacco addiction and cessation.